Adamas Pharmaceuticals (ADMS +5.5%) has settled its patent infringement litigation with Novartis’ (NVS +0.1%) Sandoz unit related to Parkinson’s disease dyskinesia med Gocovri (amantadine).
Sandoz will be allowed to launch its generic version on March 4, 2030 or earlier under certain circumstances.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.